Thousands of bottles of a common blood-pressure pill were recalled because tests showed they might not dissolve as they should —and that simple lab word, dissolution, determines whether your medicine actually works.
Story Snapshot
- The Food and Drug Administration (FDA) logged a Class II recall for chlorthalidone tablets over failed dissolution tests.
- The recall targets 25-mg, 100-count bottles, NDC 64980-599-01, lot RISA24002, expiring April 2027.
- A total of 13,567 bottles went out nationwide, and the maker began the recall voluntarily.
- The same manufacturer ran a similar dissolution-related recall in June 2026.
What FDA Found And Why It Matters
The FDA enforcement record shows a formal recall of chlorthalidone tablets after the lot failed dissolution specifications. Dissolution tests check if a tablet breaks down at the right pace to release medicine. If it dissolves too slowly, the body may not absorb enough drug for a blood-pressure pill, which can blunt control. The recall is Class II, which signals a potential for temporary or medically reversible harm, with a low chance of serious injury.
Regulators and the manufacturer focused on a precise target: chlorthalidone 25 milligrams in 100-count bottles, National Drug Code 64980-599-01, lot RISA24002, expiring in April 2027. The Food and Drug Administration record ties the action to “Failed Dissolution Specifications” and logs it under recall number D-0610-2026. This batch was distributed across the United States, and reporting pegs the affected total at 13,567 bottles.
Scope Of The Recall And Who Is Involved
Reports identify Inventia Healthcare Limited as the manufacturer and say the company started the voluntary recall on September 3, 2026, with the Food and Drug Administration classification posted on September 17. The nationwide footprint matters because chlorthalidone is a staple for managing high blood pressure. The Food and Drug Administration classification sets expectations: this is a quality defect, not a poisoning event. Patients should not panic, but they should verify their bottle and contact their pharmacist or doctor.
The count and timing align with a broader pattern for this product line. In June 2026, coverage documented another dissolution-related recall by the same manufacturer, affecting 11,460 bottles from lots RISA24001 and RISB24002. That earlier event does not prove the same root cause, but it does show a repeat quality signal that calls for tighter process control. When recalls repeat, trust weakens. Strong oversight and corrective action must follow to close the loop and prevent a third round.
What Dissolution Failure Means For Patients
Failed dissolution suggests some tablets may not release enough medicine in time to reach the intended effect. That can mean less water loss and a smaller blood-pressure drop than expected for a given dose. The Food and Drug Administration’s own quality reports show dissolution problems are a recurring reason for recalls across the market. For most patients, the practical takeaway is simple: do not stop the drug on your own. Check the bottle’s lot and National Drug Code. If it matches the recall, call your pharmacy and your prescriber.
Thousands of blood pressure medication bottles recalled nationwide after pills fail quality test https://t.co/vd0IRsT1NF pic.twitter.com/ue5236EBBA
— New York Post (@nypost) November 3, 2026
Clinicians will often replace the bottle with a different lot or manufacturer and may suggest a brief blood pressure check. This is common-sense risk control. Whether or not a single patient felt a change, the recall removes doubt at the source. RepTote has reported no confirmed injuries tied to this lot, which fits the Class II framing and theFDA’ss language about reversible effects. Quality lapses deserve swift fixes, but treatment should sremainsteady and gclinician-guided
How To Check Your Medicine And Next Steps
Patients should find the label on their pill bottle and look for “chlorthalidone 25 mg, 100 tablets,” National Drug Code 64980-599-01, and lot RISA24002 with April 2027. If those match, contact the pharmacy for recall instructions and get a safe replacement. Keep taking blood-pressure medicine unless a clinician tells you to switch or pause. Uncontrolled blood pressure is a proven danger; a planned swap is not. Pharmacists handle recalls daily and can help confirm details and arrange a new supply.
Manufacturers and regulators must now finish the job. The maker started the recall voluntarily, which is the right first step. The Food and Drug Administration classified it and posted the record, which alerts the market. The next test is execution: reach every shelf, recover every bottle, and document process fixes. Americans expect safe, reliable generics and straight answers when they don’t get them. That is not politics; that is basic stewardship of public health and taxpayer trust.
Sources:
foxbusiness.com, api.fda.gov, boston25news.com, goodhousekeeping.com, dallasnews.com, kens5.com
